Caveolin 1 mRNA is overexpressed in malignant renal tissue and might serve as a novel diagnostic marker for renal cancer

Biomarkers in Medicine

Volumn 5, Issue 2, 2011, Pages 219-225

  Waalkes, Sandra ^a   Eggers, Hendrik ^a   Blasig, Hanna ^a   Atschekzei, Faranaz ^a   Kramer, Mario W ^a   Hennenlotter, Jörg ^b   Tränkenschuh, Wolfgang ^a   Stenzl, Arnulf ^b   Serth, Judiergen ^a   Schrader, Andres J ^c   Kuczyk, Markus A ^a   Merseburger, Axel S ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c UNIVERSITY OF ULM MEDICAL SCHOOL   (Germany)

Author keywords

adhesion molecules; biomarkers; caveolin 1; renal cell cancer; targeted therapy; tumor aggressiveness

Indexed keywords

BIOLOGICAL MARKER; CAVEOLIN 1; MESSENGER RNA; TUMOR MARKER;

ADULT; ADVANCED CANCER; ARTICLE; CANCER STAGING; CARCINOGENESIS; CLEAR CELL CARCINOMA; CONTROLLED STUDY; DISTANT METASTASIS; FEMALE; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; KIDNEY CANCER; KIDNEY PARENCHYMA; KIDNEY TUMOR; MAJOR CLINICAL STUDY; MALE; PAPILLARY CARCINOMA; PROGNOSIS; PROTEIN EXPRESSION; RNA EXTRACTION; TISSUE SPECIFICITY;

CARCINOMA, RENAL CELL; CAVEOLIN 1; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 79953838810     PISSN: 17520363     EISSN: None     Source Type: Journal    
DOI: 10.2217/bmm.11.12     Document Type: Article

References (37)

1. Schrader AJ, Rustemeier J, Rustemeier JC et al.: Overweight is associated with improved cancer-specifc survival in patients with organ-confned renal cell carcinoma. J. Cancer Res. Clin. Oncol. 135(12), 1693-1699 (2009).
2. Schrader AJ, Sevinc S, Olbert PJ, Hegele A, Varga Z, Hofmann R: [Gender-specifc characteristics and survival of renal cell carcinoma]. Der Urologe. Ausg. 47(9), 1182, 1184-1186 (2008).
3. Tamaskar I, Choueiri TK, Sercia L, Rini B, Bukowski R, Zhou M: Differential expression of caveolin-1 in renal neoplasms. Cancer 110(4), 776-782 (2007). (Pubitemid 47257654)
4. Engelman JA, Wykoff CC, Yasuhara S, Song KS, Okamoto T, Lisanti MP: Recombinant expression of caveolin-1 in oncogenically transformed cells abrogates anchorage-independent growth. J. Biol. Chem. 272(26), 16374-16381 (1997). (Pubitemid 27276462)
5. Engelman JA, Zhang XL, Galbiati F, Lisanti MP: Chromosomal localization, genomic organization, and developmental expression of the murine caveolin gene family (Cav-1,-2 and-3). Cav-1 and Cav-2 genes map to a known tumor suppressor locus (6-A2/7q31). FEBS Lett. 429(3), 330-336 (1998). (Pubitemid 28300386)
6. Engelman JA, Zhang XL, Lisanti MP: Genes encoding human caveolin-1 and-2 are co-localized to the D7S522 locus (7q31.1), a known fragile site (FRA7G) that is frequently deleted in human cancers. FEBS Lett. 436(3), 403-410 (1998). (Pubitemid 28482971)
7. Engelman JA, Zhang XL, Lisanti MP: Sequence and detailed organization of the human caveolin-1 and-2 genes located near the D7S522 locus (7q31.1). Methylation of a CpG island in the 5́ promoter region of the caveolin-1 gene in human breast cancer cell lines. FEBS Lett. 448(2-3), 221-230 (1999). (Pubitemid 29168492)
8. Furuchi T, Anderson RG: Cholesterol depletion of caveolae causes hyperactivation of extracellular signal-related kinase (ERK). J. Biol. Chem. 273(33), 21099-21104 (1998). (Pubitemid 28385396)
9. Galbiati F, Volonte D, Engelman JA et al.: Targeted downregulation of caveolin-1 is suffcient to drive cell transformation and hyperactivate the p42/44 MAP kinase cascade. EMBO J. 17(22), 6633-6648 (1998). (Pubitemid 28521797)
10. Koleske AJ, Baltimore D, Lisanti MP: Reduction of caveolin and caveolae in oncogenically transformed cells. Proc Natl Acad. Sci. USA 92(5), 1381-1385 (1995).
11. Lee SW, Reimer CL, Oh P, Campbell DB, Schnitzer JE: Tumor cell growth inhibition by caveolin re-expression in human breast cancer cells. Oncogene 16(11), 1391-1397 (1998). (Pubitemid 28151846)
12. Sager R, Sheng S, Anisowicz A et al.: RNA genetics of breast cancer: maspin as paradigm. Cold Spring Harb. Sym. 59, 537-546 (1994).
13. Scherer PE, Okamoto T, Chun M, Nishimoto I, Lodish HF, Lisanti MP: Identifcation, sequence, and expression of caveolin-2 defnes a caveolin gene family Proc Natl Acad. Sci. USA 93(1), 131-135 (1996). (Pubitemid 26041482)
14. Campbell L, Gumbleton M, Griffths DF: Caveolin-1 overexpression predicts poor disease-free survival of patients with clinically confned renal cell carcinoma. Br. J. Cancer 89(10), 1909-1913 (2003). (Pubitemid 37533269)
15. Guinan P, Sobin LH, Algaba F et al.: TNM staging of renal cell carcinoma: Workgroup No. 3. Union International Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer 80(5), 992-993 (1997).
16. Fuhrman SA, Lasky LC, Limas C: Prognostic signifcance of morphologic parameters in renal cell carcinoma. Am. J. Surg. Pathol. 6(7), 655-663 (1982). (Pubitemid 13234762)
17. Stenzl A, deKernion JB: Pathology, biology, and clinical staging of renal cell carcinoma. Semin. Oncol. 16(1 Suppl. 1), 3-11 (1989). (Pubitemid 19086385)
18. -ΔΔCτ method. Methods 25(4), 402-408 (2001). (Pubitemid 34164012)
19. Schmittgen TD, Livak KJ: Analyzing real-time PCR data by the comparative C(T) method. Nat. Protoc 3(6), 1101-1108 (2008). (Pubitemid 351818697)
20. Satoh T, Yang G, Egawa S et al.: Caveolin-1 expression is a predictor of recurrence-free survival in pT2N0 prostate carcinoma diagnosed in Japanese patients. Cancer 97(5), 1225-1233 (2003). (Pubitemid 36237308)
21. Ito Y, Yoshida H, Nakano K et al.: Caveolin-1 overexpression is an early event in the progression of papillary carcinoma of the thyroid. BMJ 86(6), 912-916 (2002). (Pubitemid 34271027)
22. Rajjayabun PH, Garg S, Durkan GC, Charlton R, Robinson MC, Mellon JK: Caveolin-1 expression is associated with high-grade bladder cancer. Urology 58(5), 811-814 (2001).
23. Suzuoki M, Miyamoto M, Kato K et al.: Impact of caveolin-1 expression on prognosis of pancreatic ductal adenocarcinoma. BMJ 87(10), 1140-1144 (2002). (Pubitemid 35418110)
24. Ando T, Ishiguro H, Kimura M et al.: The overexpression of caveolin-1 and caveolin-2 correlates with a poor prognosis and tumor progression in esophageal squamous cell carcinoma. Oncol. Rep. 18(3), 601-609 (2007).
25. Bender FC, Reymond MA, Bron C, Quest AF: Caveolin-1 levels are down-regulated in human colon tumors, and ectopic expression of caveolin-1 in colon carcinoma cell lines reduces cell tumorigenicity. Cancer Res. 60(20), 5870-5878 (2000).
26. Racine C, Belanger M, Hirabayashi H, Boucher M, Chakir J, Couet J: Reduction of caveolin 1 gene expression in lung carcinoma cell lines. Biochem. Biophys. Res. Commun. 255(3), 580-586 (1999). (Pubitemid 29294841)
27. Wiechen K, Diatchenko L, Agoulnik A et al.: Caveolin-1 is down-regulated in human ovarian carcinoma and acts as a candidate tumor suppressor gene. Am. J. Pathol. 159(5), 1635-1643 (2001). (Pubitemid 33062506)
28. Wiechen K, Sers C, Agoulnik A et al.: Down-regulation of caveolin-1, a candidate tumor suppressor gene, in sarcomas. Am. J. Pathol. 158(3), 833-839 (2001). (Pubitemid 32221776)
29. Yu JH, Wei Q, Qi FJ, Xu HT, Wang EH: [Signifcance of caveolin-1 expression in primary lung cancer]. Zhonghua Bing Li Xue Za Zhi 35(11), 664-668 (2006). (Pubitemid 46173569)
30. Horiguchi A, Asano T, Asakuma J, Asano T, Sumitomo M, Hayakawa M: Impact of caveolin-1 expression on clinicopathological parameters in renal cell carcinoma. J. Urol. 172(2), 718-722 (2004). (Pubitemid 38900248)
31. Joo HJ, Oh DK, Kim YS, Lee KB, Kim SJ: Increased expression of caveolin-1 and microvessel density correlates with metastasis and poor prognosis in clear cell renal cell carcinoma. BJU Int. 93(3), 291-296 (2004). (Pubitemid 38253572)
32. Karam JA, Lotan Y, Roehrborn CG, Ashfaq R, Karakiewicz PI, Shariat SF: Caveolin-1 overexpression is associated with aggressive prostate cancer recurrence. Prostate 67(6), 614-622 (2007). (Pubitemid 46685281)
33. Thompson TC, Tahir SA, Li L et al.: The role of caveolin-1 in prostate cancer: clinical implications. Prostate Can. Prostatic Dis. 13(1), 6-11 (2009).
34. Yang G, Truong LD, Wheeler TM, Thompson TC: Caveolin-1 expression in clinically confned human prostate cancer: a novel prognostic marker. Cancer Res. 59(22), 5719-5723 (1999).
35. Loeb LA, Loeb KR, Anderson JP: Multiple mutations and cancer. Proc Natl Acad. Sci. USA 100(3), 776-781 (2003). (Pubitemid 36183906)
36. Campbell L, Jasani B, Edwards K, Gumbleton M, Griffths DF: Combined expression of caveolin-1 and an activated AKT/mTOR pathway predicts reduced disease-free survival in clinically confned renal cell carcinoma. Br. J. Cancer 98(5), 931-940 (2008). (Pubitemid 351341603)
37. Kondagunta GV, Drucker B, Schwartz L et al.: Phase II trial of bortezomib for patients with advanced renal cell carcinoma. J. Clin. Oncol. 22(18), 3720-3725 (2004). (Pubitemid 41095212)